Blogs

The era of big pharma as product-first companies must end, as services become the larger priority.

To rebuild trust, companies should focus on transparent, neutral content incorporating medical expertise and regularly seeking HCP feedback.

Agency will be reorganizing field force and compliance functions.

EU proposal focuses on a subset of underserved rare diseases—exploring the gaps in those conditions for which there is no approved treatment option.

Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.

Panel at recent Talk Health event at Le Méridien, in Philadelphia, PA, on September 11th, 2023, focused on what success looks like in audio from a publisher, vendor, and HCP perspectives.

With lessons from COVID now established, concrete ideas on improving drug development strategy for future health threats are beginning to take shape.

If a future Supreme Court ruling on diversity were to be applicable to clinical research, the FDA’s positions on diversity will take on even more importance.

In this Q&A, David Esposito, CEO of ONL Therapeutics provides a glimpse into the company's mission, challenges, and strategies associated with clinical trials.

Using IROs can offer the opportunity for doctors to incorporate clinical research as a care option in their practices.

Insights from Clinical Quality Oversight Forum.

Jeff Liter, CEO of Luminary Therapeutics discusses the company's unique approach in the fast-evolving landscape of cancer treatment.

Changing the expectations of the feasibility study can improve the process.

Nathalie Dubois-Stringfellow, Sangamo’s chief development officer discusses the company's diverse clinical programs, strategic collaborations, including a partnership with Pfizer, and the crucial role of patient safety.

Jim Kremidas, former executive director, Association of Clinical Research Professionals, shares his experiences as a patient in clinical trials.

How retail pharmacies can harness their resources to improve clinical trial access.

In this Q&A, Craig Lipset offers additional insights following the announcement that CVS will be closing its clinical trial services business by the end of the year.

In this Q&A, John Kastelein, MD, founder and chief scientific officer, NewAmsterdam Pharma, discusses the challenges and opportunities within the cardiovascular field, exploring the current landscape for lipid-lowering therapies and the unique potential advantages of CETP inhibitors.

EU’s sweeping push for major pharma reforms to impact the daily practice of clinical trials community.

Dissecting the EMA’s new annual report on milestones reached in clinical research and public health.

The journey of CVS Health’s clinical trials unit serves as a speculative case study, reminding us that venturing into new market areas, even for established companies, necessitates a careful evaluation of strategic fit, competition, infrastructure, financial constraints, and industry trends.

Key considerations for successful implementation in decentralized clinical trials.

Agency seeks added resources and new approaches to accelerate more of these promising treatments to the market.

New European report digs deeper into the potential of digital health-driven outcome measures—perhaps a hopeful step in the journey from theory to practice.

Master protocols helped accelerate research during the pandemic in the EU. How can US companies learn from this and start preparing master protocols now?

The Supreme Court’s emergency action maintaining access to mifepristone fails to protect agency from future rulings that could subvert drug approval process.

Grading the government’s formal response to reform efforts hopeful of boosting UK’s sagging global standing in drug development.